{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:24:54Z","timestamp":1789770294459,"version":"4.0.1"},"reference-count":8,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,3,11]],"date-time":"2011-03-11T00:00:00Z","timestamp":1299801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:p> <jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003Oral contraceptives are a widely prescribed means of birth control that requires the maintenance of adequate pharmacokinetics of the active components to maintain efficacy.<\/jats:p><jats:p>\u2022\u2003Oral contraceptive use in HIV\u2010infected women is widespread and may often occur in women receiving raltegravir as part of their antiretroviral therapy.<\/jats:p><jats:p>\u2022\u2003Given the prevalence of oral contraceptive use and likely need for co\u2010administration with raltegravir, combination administration should be studied to assess the safety and the pharmacokinetics of the oral contraceptive components.<\/jats:p><jats:p> <jats:bold>WHAT THIS STUDY ADDS<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003This study is the first to provide the practitioner with a detailed description of the influence of raltegravir on the pharmacokinetics of a triphasic oral contraceptive.<\/jats:p><jats:p>\u2022\u2003This study demonstrates that raltegravir does not meaningfully alter the pharmacokinetics of the estrogen or progestin components of such oral contraceptives.<\/jats:p><jats:p>\u2022\u2003This paper provides confidence to the practitioner that there will be no clinically meaningful interaction that would preclude the concurrent use of raltegravir and such oral contraceptives in combination.<\/jats:p><jats:p><jats:bold>AIMS<\/jats:bold> Oral contraceptives such as norgestimate\u2013ethinyl estradiol (Ortho Tri\u2010Cyclen\u00ae) are commonly prescribed in the HIV\u2010infected patient population. A placebo\u2010controlled, randomized, two\u2010period crossover study in healthy HIV\u2010seronegative subjects was conducted to assess the effect of raltegravir on the pharmacokinetics of the estrogen and progestin components of norgestimate\u2013ethinyl estradiol [ethinyl estradiol (EE) and norelgestromin (NGMN), an active metabolite of norgestimate (NGT)].<\/jats:p><jats:p><jats:bold>METHODS<\/jats:bold> In each of two periods, nineteen healthy women established on norgestimate\u2013ethinyl estradiol contraception (21 days of active contraception; 7 days of placebo) received either 400\u2003mg raltegravir or matching placebo twice daily on days 1\u201321. Pharmacokinetics were analysed on day 21 of each period.<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold> The geometric mean ratio (GMR) and 90% confidence interval (CI) for the EE component of norgestimate\u2013ethinyl estradiol when co\u2010administrated with raltegravir relative to EE alone was 0.98 (0.93\u20131.04) for the area under the concentration\u2013time curve from 0 to 24\u2003h (AUC<jats:sub>0\u201324\u2003h<\/jats:sub>) and 1.06 (0.98\u20131.14) for the maximum concentration of drug in the plasma (<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>); the GMR (90% CI) for the NGMN component of norgestimate\u2013ethinyl estradiol when co\u2010administered with raltegravir relative to NGMN alone was 1.14 (1.08\u20131.21) for AUC<jats:sub>0\u201324\u2003h<\/jats:sub> and 1.29 (1.23\u20131.37) for <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>. There were no discontinuations due to a study drug\u2010related adverse experience, nor any serious clinical or laboratory adverse experience.<\/jats:p><jats:p><jats:bold>CONCLUSIONS<\/jats:bold> Raltegravir has no clinically important effect on EE or NGMN pharmacokinetics. Co\u2010administration of raltegravir and an oral contraceptive containing EE and NGT was generally well tolerated; no dose adjustment is required for oral contraceptives containing EE and NGT when co\u2010administered with raltegravir.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2010.03885.x","type":"journal-article","created":{"date-parts":[[2010,12,13]],"date-time":"2010-12-13T12:44:53Z","timestamp":1292244293000},"page":"616-620","source":"Crossref","is-referenced-by-count":22,"title":["Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women"],"prefix":"10.1111","volume":"71","author":[{"given":"Matt S.","family":"Anderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison R.","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick A.","family":"Bieberdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Kost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa A.","family":"Wenning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,3,11]]},"reference":[{"key":"e_1_2_7_2_2","unstructured":"Merck and Co. I.Isentress package insert.2008."},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(02)01984-1"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600700416"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(83)90931-6"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(02)00473-0"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(99)00353-9"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000260956.61835.6d"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.01532.x"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2010.03885.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2010.03885.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T04:18:38Z","timestamp":1697429918000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2010.03885.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,11]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1111\/j.1365-2125.2010.03885.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03885.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,11]]}}}